<DOC>
	<DOCNO>NCT00764517</DOCNO>
	<brief_summary>This phase II trial study well give vorinostat , cladribine , rituximab together work treat patient mantle cell lymphoma ( MCL ) , chronic lymphocytic leukemia ( CLL ) , B cell non-Hodgkin 's lymphoma ( NHL ) return period improvement . Vorinostat may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cladribine , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Monoclonal antibody , rituximab , may block cancer growth different way target certain cell . Giving vorinostat together cladribine rituximab may kill cancer cell .</brief_summary>
	<brief_title>Vorinostat , Cladribine , Rituximab Treating Patients With Mantle Cell Lymphoma , Relapsed Chronic Lymphocytic Leukemia , Relapsed B Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine objective response rate SCR regimen ( vorinostat , cladribine , rituximab ) B-cell malignancy . II . Determine tolerability toxicity SCR regimen . SECONDARY OBJECTIVES : I . Evaluate progression free survival patient treat SCR . II . Estimate event free survival patient treat SCR . III . Determine contribution ( ) deoxyribonucleic acid ( DNA ) methylation/histone deacetylation disease progression and/or response SCR combination chemotherapy . IV . Perform scientific correlate determine SCR treatment ) associate global gene specific change transcription messenger ribonucleic acid ( mRNA ) micro ribonucleic acid ( MiRNA ) b ) act inhibitor DNA methylation c ) activate silence specific gene miRNAs . OUTLINE : Patients receive vorinostat orally ( PO ) day 1-14 , cladribine intravenously ( IV ) 2 hour day 1-5 , rituximab IV day 3 ( weekly first course ) . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 2 year every 6 month thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must able provide inform consent accord institutional guideline Patients must : 1 ) MCL ; 2 ) relapse refractory cluster differentiation ( CD ) 20 positive Bcell indolent NHL ; 3 ) relapse CLL Patients must measurable disease/disease status requirement follow : For CLL patient , symptomatic disease define International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) 2008 criteria mandate treatment For Bcell NHL patient must least one follow eligible : Positron emission tomography ( PET ) avid measurable disease compute tomography ( CT ) scan define least 1 lesion measure &gt; 2 cm single dimension Significant bone marrow and/or peripheral blood involvement NHL ( i.e . leukemic phase ) determine investigator Patients Waldenström macroglobulinemia ( WM ) exempt requirement symptomatic hyperviscosity clinically relevant cytopenia elevate serum immunoglobulin M ( IgM ) Patients must adequate bone marrow reserve indicate absolute neutrophil count ( ANC ) &gt; 1.500/mm^3 platelet count &gt; 150.000/mm^3 bone marrow involvement ; however , significant lymphoma/leukemia bone marrow infiltration , preexist hematologic parameter must meet Patients must performance status 0 , 1 , 2 accord Eastern Cooperative Oncology Group Serum creatinine &lt; 2.0 mg/dL estimate glomerular filtration rate ( GFR ) &gt; 60 mL/min Serum bilirubin = &lt; 1.5 × upper limit normal ( ULN ) Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) = &lt; 2.5 × ULN Alkaline phosphatase = &lt; 2.5 × ULN Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment Male female patient must agree use effective contraceptive method study minimum 6 month study treatment Significant hypersensitivity cladribine vorinostat ; hypersensitivity rituximab infusion exclusion criterion ; however , appropriate change infusion schedule make base current prior reaction Current concomitant chemotherapy , radiation therapy , immunotherapy specify protocol Patients diagnosis relapsed/refractory aggressive cluster differentiation antigen 20 ( CD20 ) + Bcell neoplasm define Burkitt 's lymphoma diffuse large Bcell lymphoma A diagnosis acute lymphoplasmic leukemia , lymphoblastic lymphoma Use investigational agent anticancer therapy within 2 week study entry exception hydroxyurea steroid ; patient must recover acute toxicity previous therapy Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , organ system may place patient undue risk undergo treatment Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) Pregnant lactate patient Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result Patients acquire immunodeficiency syndrome ( AIDS ) human immunodeficiency virus ( HIV ) associate complex eligible treatment Patients active hepatitis B C eligible study Patients take histone deacetylases ( HDAC ) inhibitor ; example , patient take valproic acid , must 14 day washout period prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>